Limitation of prediction on intravenous immunoglobulin responsiveness in Kawasaki disease

Korean Journal of Pediatric Infectious Diseases

Volumn 17, Issue 2, 2010, Pages 169-176

  Kim, Seong Koo ^a   Han, Ji Yoon ^a   Rhim, Jung Woo ^a   Oh, Jin Hee ^a   Han, Ji Whan ^a   Lee, Kyung Yil ^a   Kang, Jin Han ^a   Lee, Joon Sung ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Coronary artery lesion; Intravenous Immunoglobulin; Kawasaki disease; Laboratory parameters; Mucocutaneous Lymph Node Syndrome; Treatment response

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; IMMUNOGLOBULIN; LACTATE DEHYDROGENASE; SERUM ALBUMIN;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNE RESPONSE; LEUKOCYTE DIFFERENTIAL COUNT; MAJOR CLINICAL STUDY; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTIVARIATE ANALYSIS; PREDICTION; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; TREATMENT RESPONSE; UNIVARIATE ANALYSIS;

EID: 84863177899     PISSN: 12263923     EISSN: None     Source Type: Journal    
DOI: 10.14776/kjpid.2010.17.2.169     Document Type: Article

References (32)

1. Kawasaki T. Kawasaki disease. Historical background and current issues. Prog Clin Biol Res 1987;250:1-4.
2. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and longterm management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004;114:1708-33.
3. Burgner D, Harnden A. Kawasaki disease: what is the epidemiology telling us about the aetiology? Int J Infec Dis 2005;9:185-94.
4. Lee KY, Han JW, Lee JS. Kawasaki disease may be a hyperimmune reaction of genetically-susceptible children to variants of normal environmental flora. Med Hypotheses 2007;69:642-51.
5. Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, et al. High dose intravenous gamma globulin therapy for Kawasaki syndrome. Lancet 1984;2:1055-8.
6. Newberger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of Kawasaki syndrome. N Engl J Med 1991; 324:1633-9.
7. Wright DA, Newburger JW, Baker A, Sundel RP. Treatment of immunoglobulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996;128:146-9.
8. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease: US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J 1998;17: 1144-8.
9. Burns JC, Mason WH, Hauger SB, Janai H, Bastian JF, Wohrley JD, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005;146:662-7.
10. Nakano H, Ueda K, Saito A, Tsuchitani Y, Kawamori J, Miyake T, et al. Scoring method for identifying patients with Kawasaki disease at high risk coronary artery aneurysms. Am J Cardiol 1986;58:739-42.
11. Koren G, Lavi S, Rose V, Rowe R. Kawasaki disease: review of risk factors for coronary aneurysms. J Pediatr 1986;108:388-92.
12. Beiser AS, Takahashi M, Baker AL, Sundel RP, Newbur ger JW. A predictive instrument for coronary artery aneuryms in Kawasaki disease. Am J Cardiol 1998;81: 1116-20.
13. Harada K. Intravenous gamma-globulin treatment in Kawasaki disease. Acta Pediatr Jpn 1991;33:805-10.
14. McCrindle BW, Li JS, Minich LL, Colan SD, Atz AM, Takahashi M, et al. Coronary artery involvement in children with Kawasaki disease; risk factors from analysis of serial normalized measurements. Circulation 2007;116:174-9.
15. Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S. Predictors of coronary artery lesions after intravenous -globulin treatment in Kawasaki γ disease. J Pediatr 2000;137:177-80.
16. Fukunishi M, Kikkawa M, Hamana K, Onodera T, Matsuzaki K, Matsumoto Y, et al. Prediction of nonresponsiveness to intravenous high-dose γ-globulin therapy in patients with Kawasaki disease at onset. J Pediatr 2000;137:172-6.
17. Durongpisitkul K, Soongswang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C. Immunoglobulin failure and retreatment in Kawasaki diseasae. Pediatr Cardiol 2003;24:145-8.
18. Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2006;149:237-40.
19. Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006;113:2606-12.
20. Sano T, Kurotobi S, Matsuzaki K, Yamamoto T, Maki I, Miki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr 2007;166:131-7.
21. Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, et al. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan. Pediatr Infect Dis J 2008;27:155-60.
22. Tremoulet AH, Best BM, Song S, Wang S, Corinaldesi E, Eichenfield JR, et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr 2008;153:117-21.
23. Research Committee on Kawasaki disease. Report of Subcommittee on Standardization of Diagnostic Criteria and Reporting of Coronary Artery Lesions in Kawasaki disease. Tokyo, Japan: Ministry of Health and Welfare: 1984
24. Lee KY, Hong JH, Han JW, Lee JS, Lee BC, Burgner D. Features of Kawasaki disease at the extreams of age. J Paediatr Child Health 2006;42:423-7.
25. Lee KY, Han JW, Hong JH, Lee HS, Lee JS, Whang KT. Inflammatory processes in Kawasaki disease reach their peak at the sixth day of fever onset: laboratory profiles according to duration of fever. J Korean Med Sci 2004;19:765-71.
26. Checchia PA, Borensztajn J, Schulman ST. Circulating cardiac troponin I levels in Kawasaki disease. Pediatr Cardiol 2001;22:102-6.
27. Kelley-Hedgepeth A, Lloyd-Jones DM, Colvin A, Matthews KA, Johnston J, Sowers MR, et al. Ethnic differences in C-reactive protein concentration. Clin Chem 2008;54:1027-37.
28. Sakata K, Hamaoka K, Ozawa S, Niboshi A, Yoshihara T, Nishiki T, et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. Eur J Pediatr 2007;16:565-71.
29. Lee KY, Lee HS, Hong JH, Han JW, Lee JS, Whang KT. High-dose intravenous immunoglobulin downregulates the activated levels of inflammatory indices except erythrocyte sedimentation rate in acute stage of Kawasaki disease. J Trop Pediatr 2005;51:98-101.
30. Hwang JY, Lee KY, Rhim JW, Youn YS, Oh JH, Han JW, et al. Assessment of intravenous immunoglobulin non-responders in Kawasaki disease. Arch Dis Child 2010 Jun 15. [Epub ahead of print]
31. Kushner HI, Macnee RP, Burns JC. Kawasaki disease in India: increasing awareness or increased incidence? Perspect Biol Med 2009;52:17-29.
32. Du ZD, Zhao D, Du J, Zhang YL, Lin Y, Liu C, et al. Epidemiologic study on Kawasaki disease in Beijing from 2000 through 2004. Pediatr Infect Dis J 2007;26: 449-51.